Market Access News | pharmaphorum

News

NICE rejects Alnylam and Akcea's amyloidosis drugs

NICE has rejected two pioneering drugs for the rare inherited condition, hereditary transthyretin-related amyloidosis (hATTR) in first draft guidance.

News

Pills spilling out of a prescription bottle on 100 dollar paper currency

Generics firms the 'biggest cartel in US history' - report

US authorities looking into price fixing in the generics industry are now investigating 16 companies and the price of at least 300 drugs, according to a press report.

News

NICE okays UCB's Cimzia, nixes Almirall's Ilumetri, in psori...

NICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but decided that Almirall’s rival Ilumetri does not represent good value for m

News

Boehringer Ingelheim axes biosimilars development outside US

Boehringer Ingelheim has said it has axed ex-US development of its biosimilars, focusing instead on getting its Humira near-copy on the US market as soon as possible.

News

NICE approves Bayer’s liver cancer drug

NICE has given Bayer’s advanced liver cancer therapy Stivarga (regorafenib) the go-ahead after it undertook a rapid review following earlier guidance that rejected the drug.

News

Mundipharma's Neulasta biosimilar approved in EU

A second cut-price biosimilar of Amgen’s Neulasta (pegfilgrastim) long-acting white blood cell booster is to hit the EU market after the European Commission approved Mundipharma’s Pelmeg.

NICE rejects Alnylam and Akcea's amyloidosis drugs

Generics firms the 'biggest cartel in US history' - report

NICE okays UCB's Cimzia, nixes Almirall's Ilumetri, in psori...

Boehringer Ingelheim axes biosimilars development outside US

NICE approves Bayer’s liver cancer drug

Mundipharma's Neulasta biosimilar approved in EU

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks